Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
QT variability merits prospective validation as a torsades marker; leaves open routine clinical adoption over QTc.
The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline E14 recommends 'Thorough QT Study' as a standard assessment of drug-induced QT interval prolongation. At the same time, the value of drug-induced QTc prolongation as a surrogate marker for risk of life-threatening polymorphic ventricular tachycardia known as torsades des pointes remains controversial. Beat-to-beat variability of QT interval was recently proposed as an alternative metric. The following review addresses mechanisms of beat-to-beat QT variability, methods of QT interval variability measurements, and its prognostic value in clinical studies.
No takes yet. Share an insight, caveat, or question.
Tereshchenko et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: